CytoTherapeutics, Inc., Neocrin deal

CTII will receive a 10 percent equity interest in Neocrin. CTII will retain its proprietary membrane technology, which is not included in the agreement. Neocrin will use membrane technology developed by Baxter Healthcare Corp. ...